Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial
Official title:
A Phase I Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors
This phase I clinical trial is studying the side effects and best dose of IMC-A12 in treating young patients with relapsed or refractory Ewing sarcoma/peripheral primitive neuroectodermal tumor or other solid tumors. Monoclonal antibodies, such as IMC-A12, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them.
PRIMARY OBJECTIVES:
I. To estimate the maximum tolerated dose (MTD) or recommended phase II dose of IMC-A12
(cixutumumab) in children with relapsed or refractory solid tumors using a limited
dose-escalation strategy.
II. To define and describe the toxicities of this drug in children with relapsed or
refractory solid tumors.
III. To characterize the pharmacokinetics of this drug in children with relapsed or
refractory solid tumors.
SECONDARY OBJECTIVES:
I. To preliminarily define the antitumor activity of this drug in children with relapsed or
refractory solid tumors within the confines of a phase I study.
II. To obtain initial phase II efficacy data on the antitumor activity of this drug in
children with Ewing sarcoma/peripheral primitive neuroectodermal tumor (PNET).
III. To examine change in IGF-IR and insulin receptor (IR) levels and IGF-IR and IR
activation in lymphocytes as biomarkers of IMC-A12 action and specificity.
IV. To evaluate the effect of this drug on circulating levels of proteins involved in linear
growth and glucose homeostasis, including IGF-I, IGF-II, IGF-BP3, growth hormone, insulin,
and C-peptide.
V. To develop exploratory data concerning biomarkers of activity.
OUTLINE: This is a dose-escalation study.
Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats
every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease
progression.
Patients undergo blood sample collection periodically for pharmacokinetic, immunogenicity,
and other correlative studies. Samples are analyzed for serum levels of IGF-I, IGF-II,
IGF-BP3, growth hormone, insulin, and C-peptide; trough concentrations and PK sampling; and
biomarkers, including IGF-IR expression and phosphorylation and insulin receptor expression
and phosphorylation via immunoprecipitation and Western immunoblotting. Tumor tissue samples
from patients with Ewing sarcoma/peripheral PNET are banked for future research.
After completion of study treatment, patients are followed at 30 days.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01164163 -
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
|
Phase 1 | |
Completed |
NCT00985868 -
AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors
|
Phase 1 | |
Terminated |
NCT00949117 -
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
|
Phase 2 | |
Completed |
NCT00253474 -
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
|
Phase 1 | |
Completed |
NCT00281944 -
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00084695 -
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
Phase 2 | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Completed |
NCT00003070 -
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
|
Phase 3 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003754 -
Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers
|
Phase 2 | |
Completed |
NCT00004005 -
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
|
Phase 2 | |
Completed |
NCT00016861 -
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
|
Phase 1 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00898794 -
Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
|
N/A | |
Terminated |
NCT00429702 -
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
|
Phase 2 | |
Completed |
NCT00387920 -
Sunitinib in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT00459238 -
Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants
|
N/A | |
Completed |
NCT00138216 -
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
|
Phase 1 | |
Terminated |
NCT00176540 -
Dextromethorphan in Treating Patients With Fatigue Caused by Cancer
|
N/A |